Abstracts Archive - Page 1362 of 2607 - ACR Meeting Abstracts

Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 2638 • 2018 ACR/ARHP Annual Meeting
Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis
Phillip Aleksiejuk¹ and Elizabeth Ortiz², ¹Rheumatology, University of Southern California, Los Angeles, CA, ²Department of Rheumatology, University of Southern California, Los Angeles, CA
Background/Purpose: Lupus nephritis is one of the most common and severe manifestations of patients with SLE. Studies assessing the use of Tacrolimus (TAC) in lupus…
Abstract Number: 2639 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Tracy Driver¹, Maureen A. McMahon², Betty Tsao³ and Jennifer M. Grossman⁴, ¹Medicine, Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Osteoporosis is common in patients with systemic lupus erythematosus (SLE). Guidelines for the treatment and prevention of glucocorticoid induced osteoporosis (GIOP) are detailed for…
Abstract Number: 2640 • 2018 ACR/ARHP Annual Meeting
Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?
María Fernanda Zavala-Miranda¹, Samuel Govea-Peláez², Ricardo Vázquez-Rodríguez², Roberto Reyna², Sandra Morales², Diana Gómez-Martín³, Jorge Alcocer-Varela³, Javier Merayo-Chalico² and Ana Barrera-Vargas², ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Hematologic manifestations are found in up to 30% of SLE patients. Although splenectomy is considered an acceptable therapeutic option for both refractory thrombocytopenia and…
Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
Abstract Number: 2642 • 2018 ACR/ARHP Annual Meeting
Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE
Jinshan Shen¹, Orestis Papasouliotis², Eileen Samy¹, Philipp Haselmayer³, Peter Chang⁴, Victor Ona¹ and Amy H. Kao¹, ¹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ²Merck Institute for Pharmacometrics, an affiliate of Merck KGaA, Darmstadt, Germany, Lausanne, Switzerland, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA
Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and…
Abstract Number: 2643 • 2018 ACR/ARHP Annual Meeting
Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
Zahi Touma¹, Murray Urowitz², Dafna D Gladman², Carrie Wagner³, Bei Zhou³, Robert Gordon³, Benjamin Hsu³, Marc Chevrier³ and Shawn Rose³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of the cytokines IL-12 & IL-23, is being investigated in patients (pts) w/…
Abstract Number: 2644 • 2018 ACR/ARHP Annual Meeting
Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)
Zahi Touma¹, Dafna D Gladman², Jiandong Su¹, Nicole Anderson³ and Murray Urowitz², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a valid index able to measure disease activity while accounting for glucocorticoid (GC)…
Abstract Number: 2645 • 2018 ACR/ARHP Annual Meeting
The Impact of Metformin on Disease Activity in Systemic Lupus Erythematosus
Cara McLeod¹, Gbemisola Olayemi¹, Nitasha Bhatia², Frank Migliore³ and Robert Quinet¹, ¹Rheumatology, Ochsner Medical Center, New Orleans, LA, ²Ochsner Medical Center, New Orleans, LA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Metformin is a mainstay of therapy for type 2 diabetes mellitus. Newer evidence suggests that metformin may reduce lupus flares. An entity called neutrophil…
Abstract Number: 2646 • 2018 ACR/ARHP Annual Meeting
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record
Wenlu Xiong¹, J.B. Boone¹, Cecilia P. Chung¹, Leslie Crofford² and April Barnado², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data…
Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting
Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data
Manish Rathi¹, Aman Sharma², Joyita Sharma³ and Krishan L Gupta³, ¹Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ³Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarrh, India
Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…
Abstract Number: 2648 • 2018 ACR/ARHP Annual Meeting
Relationship between Damage and Mortality in Juvenile-Onset Systemic Lupus Erythematosus: Cluster Analyses in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry
JM Pego-Reigosa¹, TC Salman-Monte², Irene Altabás-González³, Iñigo Rúa-Figueroa⁴, Jacobo de Uña⁵, V Balboa-Barreiro⁶, Francisco Javier López Longo⁷, María Galindo⁸, Jaime Calvo-Alen⁹, Alejandro Olivé-Marqués¹⁰, Coral Mouriño-Rodriguez¹¹, Eva Tomero¹², Maria Loreto Horcada¹³, Ana Sánchez Atrio¹⁴, Carlos Alberto Montilla-Morales¹⁵, Eva Salgado¹⁶, Elvira Diez Alvarez¹⁷, Ricardo Blanco¹⁸, Jose Luis Andreu¹⁹, O Fernández-Berrizbeitia²⁰, José Hernández Beiraín²¹, Marian Gantes²², Blanca Hernández-Cruz²³, Angela Pecondon-Español²⁴, Carlos Marras Fernandez-Cid²⁵, María Gema Bonilla Hernán²⁶, Jesús García-Villanueva²⁷ and Vicente Torrente²⁸, ¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ²Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ³Rheumatology, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁵Statistics and OR, Vigo University, Vigo, Spain, ⁶Department of Statistics and OR, Vigo University, Vigo (Spain), Vigo, Spain, ⁷Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ¹⁰Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹¹Rheumatology, Rheumatology Section, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain, Vigo, Spain, ¹²Rheumatology, Hospital de La Princesa. Madrid. Spain, Madrid, Spain, ¹³Rheumatology, Hospital de Navarra, Pamplona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ¹⁵Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁶RheumatologyDepartment, Hospital Complex of Ourense, Ourense (Spain), Ourense, Spain, ¹⁷Complejo Asistencial Universitario de León, León, Spain, ¹⁸Rheumatology Department,, Hospital Marqués de Valdecilla, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Rheumatology Department Basurto Hospital, País Vasco, Basurto (Spain), Bilbao, Spain, ²¹Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²²Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ²³Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁴Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ²⁵Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ²⁶Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²⁷HOSPITAL RAMÓN Y CAJAL, Madrid, Spain, ²⁸Hospital de dia Baix de LLobregat, LLobregat, Spain
Background/Purpose: To identify patterns (clusters) of damage manifestation within a large cohort of juvenile SLE (jSLE) patients and evaluate their possible association with mortality. Methods:…
Abstract Number: 2649 • 2018 ACR/ARHP Annual Meeting
Prevalence of Cancer in Systemic Lupus Erythematosus
Ana Lucia Barbaglia¹, Maria de la Paz Leon¹, Luciana Gonzalez Lucero¹, Raul Sueldo², Maria Constanza Bertolaccini¹, Francisco Javier Hüttmann¹, Susana Mazza¹, Yessika Soria Curi¹, Maria Lilia Leguizamon¹, Mirta Santana², Liliana Galindo¹, Ramiro Maldonado¹, Veronica Bellomio¹, Maria Victoria Collado³, Romina Rojas Tessel⁴, Aciar Mariana⁴ and Eleonora Lucero¹, ¹Hospital Angel C. Padilla, Tucuman, Argentina, ²Hospital Angel C. Padilla, Tucumán, Argentina, ³Lanari Institute, Buenos Aires, Argentina, ⁴Hospital del Milagro, Salta, Argentina
- Background/Purpose: Cancer is one of the main causes of morbidity and mortality worldwide. The overall risk of cancer in SLE is higher than in…
Abstract Number: 2650 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus
Luca Iaccarino¹, Francesca Saccon¹, Alessandro Mathieu², Matteo Piga³, Angela Ceribelli⁴, Carlo Selmi⁵, Paolo Cardinaletti⁶, Armando Gabrielli⁷, Andrea Di Matteo⁸, Rossella De Angelis⁹, Paola Faggioli¹⁰, Antonella Laria¹¹, Micaela Fredi¹², Francesca Regola¹³, Angela Tincani¹², Laura Andreoli¹⁴, Giulia Pazzola¹⁵, Carlo Salvarani¹⁵, Francesco Puppo¹⁶, Ottavia Magnani¹⁶, Marcella Prete¹⁷, Elisa Gremese¹⁸, Maria Gerosa¹⁹, Tania Ubiali²⁰, Enrica Bozzolo²¹, Valentina Canti²¹, Vito Racanelli¹⁷, Fabrizio Conti²², Fulvia Ceccarelli²³, Elena Bartoloni²⁴, Roberto Gerli²⁵, Antonio Lobasso²⁶, Amato de Paulis²⁷, Ginevra De Marchi²⁸, Salvatore De Vita²⁹, Alessandra Bortoluzzi³⁰, Marcello Govoni³⁰, Francesco Benvenuti³¹, Margherita Zen³², Marta Mosca³³, Chiara Tani³⁴, Maurizio Rossini³⁵, Giovanni Orsolini³⁵, Salvatore Scarpato³⁶, Ernico Brunetta³⁷, Aurora Zumbo³⁸, Giacomo Tanti³⁹ and Andrea Doria⁴⁰, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²University of Cagliari, Cagliari, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁵Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁶University of Ancona, Ancona, Italy, ⁷Univeristy of Ancona, Ancona, Italy, ⁸Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ⁹Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ¹⁰Hospital of Legnano, Legnano, Italy, ¹¹Hospital of Magenta, Magenta, Italy, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹³University of Brescia, Brescia, Italy, ¹⁴Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹⁵University of Reggio Emilia, Reggio Emilia, Italy, ¹⁶University of Genova, Genova, Italy, ¹⁷University of Bari, Bari, Italy, ¹⁸Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ¹⁹Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ²⁰Istituto Gaetano Pini, University of Milano, Milano, Italy, ²¹Hospital San Raffaele, Milano, Italy, ²²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ²³UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, ²⁴Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁵Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁶University Federico II of Napoli, Napoli, Italy, ²⁷Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, ²⁸Hospital/University of Udine, Udine, Italy, ²⁹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ³⁰UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ³¹University of Padova, Padova, Italy, ³²Division of Rheumatology, University of Padova, Padova, Italy, ³³Rheumatology Unit, University of Pisa, Pisa, Italy, ³⁴Univeristy of Pisa, Pisa, Italy, ³⁵Rheumatology Unit, University of Verona, Verona, Italy, ³⁶Hospital of Salerno, Salerno, Italy, ³⁷Humanitas Hospital, Milano, Italy, ³⁸Humnaitas Hospital, Milano, Italy, ³⁹Catholic University of the sacred hearth, Roma, Italy, ⁴⁰University and Azienda Ospedaliera of Padova, Padova, Italy
Background/Purpose: To investigate effectiveness, safety, and predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: Four hundred and one…
Abstract Number: 2651 • 2018 ACR/ARHP Annual Meeting
Patients Characteristics and Patters of Treatment in Refractory Systemic Lupus Erythematosus Patients in the Pre-Biologic Period: Data from a Multiethnic, Multinational Latin American Lupus Cohort
Guillermo J. Pons-Estel^1,2, Marina Scolnik³, Enrique R Soriano³, Guillermina Harvey⁴, Rosana Quintana^5,6, Mercedes Garcia⁷, Verónica Saurit⁸, Cristina Drenkard⁹, Guillermo Berbotto¹⁰, Emilia Sato¹¹, Lilian Costallat¹², Eloisa Bonfa¹³, Eduardo Ferreira Borba¹⁴, Joao C. Tavares Brenol¹⁵, Nilzio A. da Silva¹⁶, Andre Cavalcanti¹⁷, Antonio Iglesias-Gamarra¹⁸, Marlene Guibert-Toledano¹⁹, Gil A. Reyes¹⁹, Loreto Massardo²⁰, Oscar Neira²¹, Mario H Cardiel²², Leonor Barile²³, Mary Carmen Amigo²⁴, Luis H. Silveira²⁵, Ignacio Garcia de la Torre²⁶, Rosa Maria Serrano⁶, Eduardo Acevedo-Vasquez²⁷, Manuel Ugarte-Gil²⁷, Ines Segami²⁸, Viviana Gervasoni⁵, Silvana Conti⁵, Rosa Chacón-Díaz²⁹, Maria H Esteva-Spinetti³⁰ and Bernardo A Pons-Estel⁶, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ⁴Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, ⁵Hospital Provincial de Rosario, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ⁷Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ⁸Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁹Medicine/Rheumatology, Emory University, Atlanta, GA, ¹⁰Sanatorio Británico, Rosario, Argentina, ¹¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹²Universidade Estadual da Campinas, Campinas, Brazil, ¹³Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ¹⁵Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, ¹⁶Universidade Federal de Goiás, Goiânia, Brazil, ¹⁷Novartis, Sao Paulo, Brazil, ¹⁸Clinical Development, Nordic Bioscience, Herlev, Denmark, ¹⁹Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, ²⁰GLADEL, Santiago, Chile, ²¹Rheumatology Section., Hospital del Salvador, Universidad de Chile., Santiago, Chile, ²²Centro de Investigación Clínica de Morelia, Morelia, Mexico, ²³Hospital Ángeles del Pedregal, Mexico, Mexico, ²⁴Rheumatology, Centro Medico ABC, Mexico, Mexico, ²⁵Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ²⁶Hospital General de Occidente, Guadalajara, Mexico, ²⁷Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²⁸Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, ²⁹Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ³⁰Hospital Central de San Cristóbal, San Cristóbal, Venezuela, San Cristóbal, Venezuela (Bolivarian Republic of)
Background/Purpose: Over the last few years, the importance of treating patients with systemic lupus erythematosus (SLE) towards achieving Remission or Low Disease Activity State has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].